IRF2BP1

IRF2BP1 is a nuclear transcriptional co-repressor that couples signal-regulated post-translational modifications to chromatin-level gene control. It binds the C-terminal repression domain of IRF-2 through a conformation-sensitive interface and represses both enhancer-activated and basal transcription independently of histone deacetylation, using an N-terminal zinc finger and a C-terminal RING finger (C3HC4) domain (PMID:12799427). The RING domain confers E3 ubiquitin ligase activity toward JDP2, thereby inhibiting ATF2-dependent transcription from CRE-containing promoters (PMID:18671972), while a conserved C4 zinc finger mediates assembly with IRF2BP2 and EAP1 into a co-repressor complex that occupies and silences targets such as FASTKD2 (PMID:21444724). IRF2BP1 repressive activity is dynamically tuned by SUMO cycling during EGFR signaling—transient deSUMOylation derepresses immediate-early genes including DUSP1, and timely reSUMOylation restores silencing (PMID:33480129)—and in breast cancer brain metastases it operates downstream of Cdk5 to suppress Stat1-dependent MHC-I antigen presentation (PMID:39304713).

1. 2003 High

   Identifying IRF2BP1 as a co-repressor that binds the IRF-2 repression domain established the gene's core function as a transcriptional silencer acting independently of HDAC activity, answering how IRF-2 mediates repression through recruited cofactors.

   Evidence Co-immunoprecipitation, nuclear localization, and transcriptional reporter assays with IRF-2 deletion/splice mutants in mammalian cells

   PMID:12799427

   Open questions at the time

   • Endogenous genomic targets of IRF2BP1 repression were not identified
   • Mechanism by which repression occurs without HDAC involvement was not resolved
   • Whether the RING finger domain has catalytic activity was untested
2. 2008 Medium

   Demonstrating that the RING domain functions as an E3 ubiquitin ligase for JDP2, and that IRF2BP1 represses ATF2/CRE-driven transcription, expanded the gene's mechanism beyond simple co-repressor binding to include enzymatic substrate ubiquitination.

   Evidence In vitro and in vivo ubiquitination assays with RING-domain constructs and transcriptional reporter assays

   PMID:18671972

   Open questions at the time

   • Whether JDP2 ubiquitination leads to its degradation or non-proteolytic signaling was not resolved
   • No in vivo demonstration that E3 ligase activity is required for co-repressor function
   • Single laboratory finding without independent replication
3. 2011 High

   Showing that IRF2BP1 assembles with IRF2BP2 and EAP1 via C4 zinc fingers into a co-repressor complex that occupies the FASTKD2 promoter revealed that IRF2BP1 functions within a multi-subunit repressive complex rather than solely as an IRF-2 adaptor.

   Evidence Reciprocal co-immunoprecipitation, domain mapping, ChIP, knockdown, and microarray in breast cancer cell lines

   PMID:21444724

   Open questions at the time

   • Genome-wide target repertoire of the ternary complex was not defined
   • Structural basis of the C4 zinc-finger-mediated trimerization is unknown
   • Functional contribution of individual subunits to repression was not fully dissected
4. 2021 High

   Quantitative SUMO proteomics revealed that IRF2BP1 repressor activity is dynamically regulated by signal-dependent SUMO cycling during EGFR signaling, establishing how extracellular cues temporally control immediate-early gene derepression (e.g., DUSP1) and re-silencing.

   Evidence Quantitative mass spectrometry SUMO proteomics, SUMOylation-deficient IRF2BP1 mutants, and transcriptional reporter assays

   PMID:33480129

   Open questions at the time

   • The SUMO E3 ligase and SENP isopeptidase responsible for IRF2BP1 cycling were not identified
   • Whether SUMO modification alters IRF2BP1 chromatin occupancy or complex assembly was not determined
   • Generality of SUMO-dependent regulation beyond EGF-stimulated cells is unknown
5. 2024 Medium

   Placing IRF2BP1 in the Cdk5–Irf2bp1–Stat1–Nlrc5 axis that suppresses MHC-I-mediated antigen presentation connected its repressive activity to immune evasion in brain-metastatic breast cancer.

   Evidence Genetic and pharmacological Cdk5 inhibition, single-cell RNA sequencing, and functional immune evasion assays in mouse models

   PMID:39304713

   Open questions at the time

   • Direct biochemical mechanism by which Cdk5 regulates IRF2BP1 (phosphorylation, stabilization) is unknown
   • Whether IRF2BP1 directly binds the Stat1 promoter or acts indirectly was not resolved
   • Findings are from mouse models; human validation is pending

• Key unresolved questions include the structural basis of IRF2BP1's interactions, the identity of the SUMO/deSUMO machinery controlling its activity, and whether its E3 ligase and co-repressor functions are separable in physiological settings.
• No structural model of IRF2BP1 or its complexes exists
• Full genome-wide target landscape across cell types has not been mapped
• Separation-of-function between RING-dependent ubiquitin ligase activity and co-repressor recruitment has not been tested in vivo